BNP Paribas Financial Markets
ACRV icon

BNP Paribas Financial Markets’s Acrivon Therapeutics ACRV Stock Holding History

BNP Paribas Financial Markets’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$881 Hold
634
– – ﹤0.01% 5484
2025
Q4 		$1.53K Sell
634
-555
-47% -$1.21K ﹤0.01% 5370
2025
Q3 		$2.15K Buy
1,189
+197
+20% +$277 ﹤0.01% 5164
2025
Q2 		$1.18K Sell
992
-344
-26% -$472 ﹤0.01% 5127
2025
Q1 		$2.71K Sell
1,336
-605
-31% -$3.26K ﹤0.01% 4943
2024
Q4 		$11.7K Buy
+1,941
New +$14.1K ﹤0.01% 4829

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BNP Paribas Financial Markets's ACRV Position: Q1 2026 in Review

BNP Paribas Financial Markets held its Acrivon Therapeutics (ACRV) position steady in Q1 2026 at 634 shares worth $881. The position accounts for ﹤0.01% of the portfolio, ranked #5484.

BNP Paribas Financial Markets first reported a position in ACRV in Q4 2024 and has held it in 6 quarters since. The position peaked at $11.7K in Q4 2024. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

  • BNP Paribas Financial Markets held 634 shares of Acrivon Therapeutics worth $881 as of Q1 2026.
  • BNP Paribas Financial Markets left its Acrivon Therapeutics share count unchanged in Q1 2026.
  • Acrivon Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5484 holding.
  • BNP Paribas Financial Markets first reported a position in Acrivon Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • BNP Paribas Financial Markets's Acrivon Therapeutics position peaked at $11.7K in Q4 2024.
  • 44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.